Vyriad has introduced G-Link, a modular platform designed to enhance T-cell targeted lentiviral vector delivery for both in vivo and ex vivo therapeutic applications. Vyriad, Inc. has introduced a new modular adaptor protein technology called G-Link™, a platform designed to…
Acuitas Therapeutics Showcases In Vivo CAR T Engineering and Lipid Innovations at ASGCT 2026 Acuitas Therapeutics concluded a prominent showing at the American Society of Gene & Cell Therapy 2026 Annual Meeting with the presentation of new research focused on…
Cosette Pharmaceuticals Enhances Commercial Leadership With Addition of Industry Veteran David Bell Cosette Pharmaceuticals has announced the appointment of David Bell as Chief Commercial Officer for its branded business, marking another step in the company’s ongoing effort to strengthen its…
Orca Bio Names Bijan Nejadnik as Chief Medical Officer Orca Bio has announced a major leadership transition as the company continues advancing toward commercialization of its high-precision cell therapy platform. The company appointed Bijan Nejadnik as its new Chief Medical…
BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment of hypertension in adults whose blood pressure remains inadequately controlled…
Lantern Pharma Reports First Quarter 2026 Results While Expanding AI-Driven Oncology and Commercial AI Platform Strategy Lantern Pharma reported operational highlights and financial results for the first quarter ended March 31, 2026, outlining continued progress across its precision oncology pipeline,…
Worldwide Clinical Trials Expands Leadership Team to Enhance Global Reach and Therapeutic Expertise Worldwide Clinical Trials, a global contract research organization (CRO) focused on delivering specialized clinical development services for the biopharmaceutical and medical device industries, has announced a series…
Affinia Therapeutics Highlights Advances in Gene Therapy Pipeline and Manufacturing at ASGCT 2026 Affinia Therapeutics showcased major progress across its cardiovascular and central nervous system gene therapy programs during multiple presentations at the 29th Annual Meeting of the American Society…
Ionis and Biogen Report Promising Phase 2 Results for Tau-Targeting Alzheimer’s Therapy Diranersen Ionis Pharmaceuticals and Biogen have announced encouraging topline findings from the Phase 2 CELIA clinical study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy designed to…
New Heart Failure 2026 Analyses Highlight Consistent Clinical Benefits of Vutrisiran Across Diverse ATTR-CM Patient Groups Alnylam Pharmaceuticals has announced new analyses from its Phase 3 HELIOS-B clinical trial evaluating vutrisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), providing…
Dyno Therapeutics Expands Frontiers Network and Unveils Second Annual Genetic Agency Technology Conference Dyno Therapeutics, a biotechnology company focused on applying artificial intelligence to advance in vivo gene delivery, has announced major updates to two of its strategic initiatives aimed…
Vetter Begins Building New Manufacturing Facility in Germany Vetter, a globally recognized Contract Development and Manufacturing Organization specializing in aseptic filling and pharmaceutical manufacturing services, has officially launched construction activities for its newest production facility in Saarlouis, Germany. The milestone…